{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:25:47Z","timestamp":1785446747133,"version":"3.56.0"},"reference-count":156,"publisher":"Bentham Science Publishers Ltd.","issue":"4","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["AIAAMC"],"published-print":{"date-parts":[[2020,10,15]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Tegaserod (Zelnorm\u00ae) is a 5-hydroxytryptamine (serotonin) type\n4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal\ntract associated with the irritable bowel syndrome with constipation (IBS-C).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The authors provide the reader with a better understanding on tegaserod mechanism\nof action, on its pharmacodynamics and pharmacokinetic properties, on safety and\ntolerability, with a summary of the key published clinical trials conducted in patients with\nirritable bowel syndrome (IBS). Its effects on colon inflammation have also been described.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Tegaserod was withdrawn in 2007 due to increased risks of cardiovascular adverse\neffects. The manufacturer denied this, because pre-existing cardiovascular disease or\nrisk factors were attributed to all affected patients. Thus, no causal relationship between\ntegaserod use and cardiovascular events was clearly shown. A matched case-control study\nof tegaserod-treated with untreated patients found no association between tegaserod and\nadverse cardiovascular outcomes. Despite its adverse effects, tegaserod resulted to be effective\nin treating chronic constipation in adult women aged &lt; 65 years with IBS-C, while\nthe safety and effectiveness of tegaserod in men with IBS-C have not been established.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Tegaserod was resubmitted to the Food and Drug Administration in 2018 for\nuse in a low-risk population. Moreover, tegaserod has also been shown to improve symptoms,\nenhance gastric accommodation and significantly attenuate visceral pain arising from\nthe colon in functional dyspepsia patients. Treatment with tegaserod seems also to exert a\nprotective effect in inflamed colons, reducing the severity of colitis in animal models.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871523018666190911121306","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T19:00:51Z","timestamp":1568401251000},"page":"342-369","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Tegaserod for the Treatment of Irritable Bowel Syndrome"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-612X","authenticated-orcid":true,"given":"Valentina Noemi","family":"Madia","sequence":"first","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universit\u00e0 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-5816","authenticated-orcid":true,"given":"Antonella","family":"Messore","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-5503","authenticated-orcid":true,"given":"Francesco","family":"Saccoliti","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-9835","authenticated-orcid":true,"given":"Valeria","family":"Tudino","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-7217","authenticated-orcid":true,"given":"Alessandro","family":"De Leo","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-4244","authenticated-orcid":true,"given":"Daniela","family":"De Vita","sequence":"additional","affiliation":[{"name":"Dipartimento di Biologia Ambientale, \u201cSapienza\u201d Universita di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-6499","authenticated-orcid":true,"given":"Martina","family":"Bortolami","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-7005","authenticated-orcid":true,"given":"Luigi","family":"Scipione","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8004-5537","authenticated-orcid":true,"given":"Ivano","family":"Pindinello","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-9029","authenticated-orcid":true,"given":"Roberta","family":"Costi","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-7666","authenticated-orcid":true,"given":"Roberto","family":"Di Santo","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, \u201cSapienza\u201d Universita\u0300 di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","volume":"10","author":"Lovell R.M.","year":"2012","unstructured":"Lovell R.M.; Ford A.C.; Global prevalence of and risk factors for irritable bowel syndrome: a meta analysis. Clin Gastroenterol Hepatol 2012,10(7),712-721.e4","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jcag\/gwy071","volume":"2","author":"Moayyedi P.","year":"2019","unstructured":"Moayyedi P.; Andrews C.N.; MacQueen G.; Korownyk C.; Marsiglio M.; Graff L.; Kvern B.; Lazarescu A.; Liu L.; Paterson W.G.; Sidani S.; Vanner S.; Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2019,2(1),6-29","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jcag\/gwy072","volume":"2","author":"Moayyedi P.","year":"2019","unstructured":"Moayyedi P.; Marsiglio M.; Andrews C.N.; Graff L.A.; Korownyk C.; Kvern B.; Lazarescu A.; Liu L.; MacQueen G.; Paterson W.G.; Sidani S.; Vanner S.J.; Sinclair P.; Marshall L.; Fernandes A.; Patient engagement and multidisciplinary involvement has an impact on clinical guideline development and decisions: a comparison of two irritable bowel syndrome guidelines using the same data. J Can Assoc Gastroenterol 2019,2(1),30-36","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12955-019-1174-1","volume":"17","author":"Faresj\u00f6 \u00c5.","year":"2019","unstructured":"Faresj\u00f6 \u00c5.; Walter S.; Norlin A.K.; Faresj\u00f6 T.; Jones M.P.; Gastrointestinal symptoms - an illness burden that affects daily work in patients with IBS. Health Qual Life Outcomes 2019,17(1),113","journal-title":"Health Qual Life Outcomes"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/fampra\/cml050","volume":"23","author":"Rubin G.","year":"2006","unstructured":"Rubin G.; De Wit N.; Meineche-Schmidt V.; Seifert B.; Hall N.; Hungin P.; The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract 2006,23(6),687-692","journal-title":"Fam Pract"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/fampra\/cmn088","volume":"26","author":"Casiday R.E.","year":"2009","unstructured":"Casiday R.E.; Hungin A.P.; Cornford C.S.; de Wit N.J.; Blell M.T.; GPs\u2019 explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam Pract 2009,26(1),34-39","journal-title":"Fam Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1155\/2003\/532138","volume":"17","author":"Bijkerk C.J.","year":"2003","unstructured":"Bijkerk C.J.; de Wit N.J.; Stalman W.A.; Knottnerus J.A.; Hoes A.W.; Muris J.W.; Irritable bowel syndrome in primary care: the patients\u2019 and doctors\u2019 views on symptoms, etiology and management. Can J Gastroenterol 2003,17(6),363-368","journal-title":"Can J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clnu.2012.05.021","volume":"32","author":"Moussa L.","year":"2013","unstructured":"Moussa L.; B\u00e9zirard V.; Salvador-Cartier C.; Bacqui\u00e9 V.; Houdeau E.; Th\u00e9odorou V.; A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin Nutr 2013,32(1),51-58","journal-title":"Clin Nutr"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8967306","volume":"2019","author":"Zhang J.J.","year":"2019","unstructured":"Zhang J.J.; Ma H.; Zhu J.Z.; Lu C.; Yu C.H.; Li Y.M.; The role of dietary energy and macronutrients intake in prevalence of irritable bowel syndromes. BioMed Res Int 2019,2019","journal-title":"BioMed Res Int"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016297","volume":"98","author":"Zhang F.M.","year":"2019","unstructured":"Zhang F.M.; Li S.; Ding L.; Xiang S.H.; Zhu H.T.; Yu J.H.; Xu G.Q.; Effectiveness of mesalazine to treat irritable bowel syndrome: a meta-analysis. Medicine (Baltimore) 2019,98(28)","journal-title":"Medicine (Baltimore)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/s0004-2803.201900000-12","volume":"56","author":"Lopes S.S.","year":"2019","unstructured":"Lopes S.S.; Miszputen S.J.; Sachs A.; Lima M.M.; Ambrogini O.; Evaluation of carbohydrate and fiber consumption in patients with irritable bowel syndrome in outpatient treatment. Arq Gastroenterol 2019,56(1),3-9","journal-title":"Arq Gastroenterol"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016068","volume":"98","author":"Liang D.","year":"2019","unstructured":"Liang D.; Longgui N.; Guoqiang X.; Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis. Medicine (Baltimore) 2019,98(27)","journal-title":"Medicine (Baltimore)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12876-019-0985-1","volume":"19","author":"Tack J.","year":"2019","unstructured":"Tack J.; Stanghellini V.; Mearin F.; Yiannakou Y.; Layer P.; Coffin B.; Simren M.; Mackinnon J.; Wiseman G.; Marciniak A.; Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol 2019,19(1),69","journal-title":"BMC Gastroenterol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MCO.0000000000000589]","volume":"22","author":"Guerreiro M.","year":"2019","unstructured":"Guerreiro M.; Sousa Guerreiro C.; Cravo M.; Irritable bowel syndrome: how can symptoms and quality of life be improved with diet? Curr Opin Clin Nutr Metab Care 2019,22(5),377-382","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2982.2008.01084.x","volume":"20","author":"Sanger G.J.","year":"2008","unstructured":"Sanger G.J.; Alpers D.H.; Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008,20(3),177-184","journal-title":"Neurogastroenterol Motil"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061482","volume":"20","author":"Baj A.","year":"2019","unstructured":"Baj A.; Moro E.; Bistoletti M.; Orlandi V.; Crema F.; Giaroni C.; Glutamatergic signaling along the microbiota-gut-brain axis. Int J Mol Sci 2019,20(6)","journal-title":"Int J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ajhp\/62.7.700","volume":"62","author":"Baker D.E.","year":"2005","unstructured":"Baker D.E.; Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 2005,62(7),700-711","journal-title":"Am J Health Syst Pharm"},{"key":"ref=18","first-page":"A638","volume":"126","author":"Di Stefano M.V.R.","year":"2004","unstructured":"Di Stefano M.V.R.; Sifrim D.; Tack J.; Effects of buspirone, a 5-HT1A receptor agonist, on oesophagea peristalsis and lower esophageal sphincter function in healthy volunteers. Gastroenterology 2004,126,A638","journal-title":"Gastroenterology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjp.0704571","volume":"135","author":"Borman R.A.","year":"2002","unstructured":"Borman R.A.; Tilford N.S.; Harmer D.W.; Day N.; Ellis E.S.; Sheldrick R.L.; Carey J.; Coleman R.A.; Baxter G.S.; 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol 2002,135(5),1144-1151","journal-title":"Br J Pharmacol"},{"key":"ref=20","first-page":"S252","volume":"7","author":"Crowell M.D.","year":"2001","unstructured":"Crowell M.D.; The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001,7(8)(Suppl.),S252-S260","journal-title":"Am J Manag Care"},{"key":"ref=21","first-page":"631","volume":"47","author":"Briejer M.R.","year":"1995","unstructured":"Briejer M.R.; Akkermans L.M.; Schuurkes J.A.; Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995,47(4),631-651","journal-title":"Pharmacol Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1021\/jm020099f","volume":"46","author":"Langlois M.","year":"2003","unstructured":"Langlois M.; Fischmeister R.; 5-HT4 receptor ligands: applications and new prospects. J Med Chem 2003,46(3),319-344","journal-title":"J Med Chem"},{"key":"ref=23","first-page":"1628","author":"Williams M.","year":"2013","unstructured":"Williams M.;  The Merck Index: an Encyclopedia of Chemicals 2013,1628","journal-title":"The Merck Index: an Encyclopedia of Chemicals"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bjp.0705929","volume":"143","author":"Beattie D.T.","year":"2004","unstructured":"Beattie D.T.; Smith J.A.; Marquess D.; Vickery R.G.; Armstrong S.R.; Pulido-Rios T.; McCullough J.L.; Sandlund C.; Richardson C.; Mai N.; Humphrey P.P.; The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004,143(5),549-560","journal-title":"Br J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003960.pub3","volume":"4","author":"Evans B.W.","year":"2007","unstructured":"Evans B.W.; Clark W.K.; Moore D.J.; Whorwell P.J.; Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007,4(4)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/S0149-2918(03)80198-4","volume":"25","author":"Rivkin A.","year":"2003","unstructured":"Rivkin A.; Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin Ther 2003,25(7),1952-1974","journal-title":"Clin Ther"},{"key":"ref=27","author":"Rossi S.","year":"2004","unstructured":"Rossi S.; AMH Pty Ltd: Australia; 27th ed, Australian Medicines Handbook 2004","journal-title":"Australian Medicines Handbook"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1097\/MJT.0000000000000947","volume":"26","author":"Marciniak T.A.","year":"2019","unstructured":"Marciniak T.A.; Serebruany V.; Should we use tegaserod for irritable bowel syndrome? Am J Ther 2019,26(3),e417-e420","journal-title":"Am J Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","volume":"97","author":"Morganroth J.","year":"2002","unstructured":"Morganroth J.; R\u00fcegg P.C.; Dunger-Baldauf C.; Appel-Dingemanse S.; Bliesath H.; Lefkowitz M.; Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002,97(9),2321-2327","journal-title":"Am J Gastroenterol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02294.x","volume":"21","author":"M\u00fcller-Lissner S.","year":"2005","unstructured":"M\u00fcller-Lissner S.; Holtmann G.; Rueegg P.; Weidinger G.; L\u00f6ffler H.; Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005,21(1),11-20","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","volume":"16","author":"Novick J.","year":"2002","unstructured":"Novick J.; Miner P.; Krause R.; Glebas K.; Bliesath H.; Ligozio G.; R\u00fcegg P.; Lefkowitz M.; A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002,16(11),1877-1888","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1136\/gut.2005.070789","volume":"54","author":"Tack J.","year":"2005","unstructured":"Tack J.; M\u00fcller-Lissner S.; Bytzer P.; Corinaldesi R.; Chang L.; Viegas A.; Schnekenbuehl S.; Dunger-Baldauf C.; Rueegg P.; A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005,54(12),1707-1713","journal-title":"Gut"},{"key":"ref=33","author":"Tegaserod N.D.A.","unstructured":"Tegaserod N.D.A.; 21-200 Supplements., Available from: [Accessed May 17, 2019]"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1021\/jm00013a010","volume":"38","author":"Buchheit K.H.","year":"1995","unstructured":"Buchheit K.H.; Gamse R.; Giger R.; Hoyer D.; Klein F.; Kl\u00f6ppner E.; Pfannkuche H.J.; Mattes H.; The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995,38(13),2331-2338","journal-title":"J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-2982.2007.01059.x","volume":"20","author":"De Maeyer J.H.","year":"2008","unstructured":"De Maeyer J.H.; Lefebvre R.A.; Schuurkes J.A.; 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008,20(2),99-112","journal-title":"Neurogastroenterol Motil"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000090309","volume":"24","author":"Tonini M.","year":"2006","unstructured":"Tonini M.; Pace F.; Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006,24(1-2),59-69","journal-title":"Dig Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2982.2005.00716.x","volume":"17","author":"Tonini M.","year":"2005","unstructured":"Tonini M.; 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005,17(5),637-642","journal-title":"Neurogastroenterol Motil"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5114\/aoms.2017.69234","volume":"15","author":"Jin M.","year":"2019","unstructured":"Jin M.; Mo Y.; Ye K.; Chen M.; Liu Y.; He C.; Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis. Arch Med Sci 2019,15(1),23-32","journal-title":"Arch Med Sci"},{"key":"ref=39","volume":"10","author":"Pittayanon R.","year":"2018","unstructured":"Pittayanon R.; Yuan Y.; Bollegala N.P.; Khanna R.; Leontiadis G.I.; Moayyedi P.; Prokinetics for functional dyspepsia. Cochrane Database Syst Rev 2018,10","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/j.gastro.2016.07.032","volume":"151","author":"Spohn S.N.","year":"2016","unstructured":"Spohn S.N.; Bianco F.; Scott R.B.; Keenan C.M.; Linton A.A.; O\u2019Neill C.H.; Bonora E.; Dicay M.; Lavoie B.; Wilcox R.L.; MacNaughton W.K.; De Giorgio R.; Sharkey K.A.; Mawe G.M.; Protective actions of epithelial 5-hydroxytryptamine 4 receptors in normal and inflamed colon. Gastroenterology 2016,151(5),933-944.e3","journal-title":"Gastroenterology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.3748\/wjg.v10.i12.1830","volume":"10","author":"Sun Y.N.","year":"2004","unstructured":"Sun Y.N.; Luo J.Y.; Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord. World J Gastroenterol 2004,10(12),1830-1833","journal-title":"World J Gastroenterol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/sj.bjp.0705762","volume":"141","author":"Crowell M.D.","year":"2004","unstructured":"Crowell M.D.; Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004,141(8),1285-1293","journal-title":"Br J Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1096\/fasebj.10.12.8903510","volume":"10","author":"Hegde S.S.","year":"1996","unstructured":"Hegde S.S.; Eglen R.M.; Peripheral 5-HT4 receptors. FASEB J 1996,10(12),1398-1407","journal-title":"FASEB J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","volume":"10","author":"Mawe G.M.","year":"2013","unstructured":"Mawe G.M.; Hoffman J.M.; Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013,10(8),473-486","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1523\/JNEUROSCI.1145-09.2009","volume":"29","author":"Liu M.T.","year":"2009","unstructured":"Liu M.T.; Kuan Y.H.; Wang J.; Hen R.; Gershon M.D.; 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci 2009,29(31),9683-9699","journal-title":"J Neurosci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2982.2004.00572.x","volume":"16","author":"Bertrand P.P.","year":"2004","unstructured":"Bertrand P.P.; Real-time detection of serotonin release from enterochromaffin cells of the guinea-pig ileum. Neurogastroenterol Motil 2004,16(5),511-514","journal-title":"Neurogastroenterol Motil"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/j.gastro.2011.12.041","volume":"142","author":"Hoffman J.M.","year":"2012","unstructured":"Hoffman J.M.; Tyler K.; MacEachern S.J.; Balemba O.B.; Johnson A.C.; Brooks E.M.; Zhao H.; Swain G.M.; Moses P.L.; Galligan J.J.; Sharkey K.A.; Greenwood-Van Meerveld B.; Mawe G.M.; Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012,142(4),844-854.e4","journal-title":"Gastroenterology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/00003495-199958030-00013","volume":"58","author":"Scott L.J.","year":"1999","unstructured":"Scott L.J.; Perry C.M.; Tegaserod. Drugs 1999,58(3),491-496","journal-title":"Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/17455057.2.1.29","volume":"2","author":"Saad R.","year":"2006","unstructured":"Saad R.; Chey W.D.; Tegaserod in the treatment of irritable bowel syndrome with constipation. Womens Health (Lond) 2006,2(1),29-42","journal-title":"Womens Health (Lond)"},{"key":"ref=50","first-page":"8898","volume":"20","author":"Jadallah K.A.","year":"2014","unstructured":"Jadallah K.A.; Kullab S.M.; Sanders D.S.; Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 2014,20(27),8898-8909","journal-title":"World J Gastroenterol"},{"key":"ref=51","first-page":"1098","volume":"258","author":"Taniyama K.","year":"1991","unstructured":"Taniyama K.; Nakayama S.; Takeda K.; Matsuyama S.; Shirakawa J.; Sano I.; Tanaka C.; Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J Pharmacol Exp Ther 1991,258(3),1098-1104","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/gut.28.1.13","volume":"28","author":"Edwards C.A.","year":"1987","unstructured":"Edwards C.A.; Holden S.; Brown C.; Read N.W.; Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut 1987,28(1),13-16","journal-title":"Gut"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2036.1987.tb00629.x","volume":"1","author":"Krevsky B.","year":"1987","unstructured":"Krevsky B.; Malmud L.S.; Maurer A.H.; Somers M.B.; Siegel J.A.; Fisher R.S.; The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987,1(4),293-304","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/00365529850166833","volume":"33","author":"Farup P.G.","year":"1998","unstructured":"Farup P.G.; Hovdenak N.; Wetterhus S.; Lange O.J.; Hovde O.; Trondstad R.; The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998,33(2),128-131","journal-title":"Scand J Gastroenterol"},{"key":"ref=55","first-page":"8","volume":"37","author":"Lewis C.","year":"2003","unstructured":"Lewis C.; The impact of direct-to-consumer advertising. FDA Consum 2003,37(2),8","journal-title":"FDA Consum"},{"key":"ref=56","author":"De Knaep A.G.M.","year":"1998","unstructured":"De Knaep A.G.M.; Moens L.J.R.; Rey M.; Synthesis of cisapride.  International Patent WO\/1998\/016511 April 231998","journal-title":"International Patent"},{"key":"ref=57","author":"Palmer R.M.J.","year":"2006","unstructured":"Palmer R.M.J.; Meyers N.L.; Knight J.; Process for the preparation of renzapride and intermediates thereof. European Patent EP1664048 (A2) June 072006","journal-title":"European Patent EP1664048 (A2)"},{"key":"ref=58","first-page":"108","volume":"1","author":"Lee M.J.","year":"2014","unstructured":"Lee M.J.; Choi S.; Im, W. 5-HT4 Receptor agonists in the treatment of gastrointestinal motility disorders: current status and perspective. Int J Gastroenterol Disorder 2014,1,108-115","journal-title":"Int J Gastroenterol Disorder"},{"key":"ref=59","author":"Noverola A.V.","year":"1979","unstructured":"Noverola A.V.; Soto J.P.; Spickett R.G.W.; Aromatic amides of heterocyclic compounds and therapeutic compositions containing same. US Patent 4,138,492 February 61979","journal-title":"US Patent 4,138,492"},{"key":"ref=60","author":"Vukics K.","year":"2003","unstructured":"Vukics K.; Fischer J.; L\u00e9vai S.; Erd\u00e9lyi P.; Process for the synthesis of mosapride. International Patent WO\/2003\/106440 December 242003","journal-title":"International Patent"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000070202","volume":"67","author":"Coremans G.","year":"2003","unstructured":"Coremans G.; Kerstens R.; De Pauw M.; Stevens M.; Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo controlled clinical trial. Digestion 2003,67(1-2),82-89","journal-title":"Digestion"},{"key":"ref=62","author":"Chai Y.","year":"2014","unstructured":"Chai Y.; Xu D.; Gong Y.; Zheng L.; Qian W.; Yang Z.; Tian Z.; Lv F.; Yuan F.; Synthesis process of prucalopride. Chinese Patent CN103664912 March 262014","journal-title":"Chinese Patent CN103664912"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1016\/j.bmcl.2012.08.051","volume":"22","author":"Long D.D.","year":"2012","unstructured":"Long D.D.; Armstrong S.R.; Beattie D.T.; Choi S.K.; Fatheree P.R.; Gendron R.A.; Genov D.; Goldblum A.A.; Humphrey P.P.; Jiang L.; Marquess D.G.; Shaw J.P.; Smith J.A.; Turner S.D.; Vickery R.G.; Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of concept in patients with chronic idiopathic constipation. Bioorg Med Chem Lett 2012,22(19),6048-6052","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=64","author":"Henschke J.P.","year":"2014","unstructured":"Henschke J.P.; Liu Y.; Xia L.; Chen Y.F.; Process for the preparation of lubiprostone. U.S. Patent 8,846,958 B2,  September 302014"},{"key":"ref=65","author":"Chen X.","year":"2017","unstructured":"Chen X.; Wu J.; Mi P.; Tao A.; Yuan J.; Linaclotide synthesis method. International Patent WO\/2017\/101810, June 222017"},{"key":"ref=66","author":"Mi P.","year":"2014","unstructured":"Mi P.; Pan J.; Ma Y.; Yuan J.; Preparation method of plecanatide. Chinese Patent CN104211777,  December 172014"},{"key":"ref=67","author":"Starke I.","year":"2002","unstructured":"Starke I.; Dahlstrom M.; Blomberg D.; Chemical compounds.International Patent WO\/2002\/050051, June 272002"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1053\/gast.2002.37095b","volume":"123","year":"2002","unstructured":"Americal Gastroenterological Association medical position statement: Irritable bowel syndrome. Gastroenterol 2002,123,2105-2107","journal-title":"Gastroenterol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12019-002-0031-y","volume":"28","author":"Frissora C.L.","year":"2002","unstructured":"Frissora C.L.; A new look at irritable bowel syndrome [IBS]: a neuroenteric disorder. Compr Ther 2002,28(3),222-231","journal-title":"Compr Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2036.1994.tb00322.x","volume":"8","author":"Poynard T.","year":"1994","unstructured":"Poynard T.; Naveau S.; Mory B.; Chaput J.C.; Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994,8(5),499-510","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/gast.2001.21908","volume":"120","author":"Camilleri M.","year":"2001","unstructured":"Camilleri M.; Management of the irritable bowel syndrome. Gastroenterology 2001,120(3),652-668","journal-title":"Gastroenterology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1751-2980.2011.00491.x","volume":"12","author":"Quigley E.M.","year":"2011","unstructured":"Quigley E.M.; Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis 2011,12(3),147-156","journal-title":"J Dig Dis"},{"key":"ref=73","unstructured":"Available from: Pharmaceuticals: restrictions in use and availability World Health Organization","journal-title":"Pharmaceuticals: restrictions in use and availability"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/147323000703500613","volume":"35","author":"Meyers N.L.","year":"2007","unstructured":"Meyers N.L.; Hickling R.I.; The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007,35(6),848-866","journal-title":"J Int Med Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/13543784.17.11.1663","volume":"17","author":"Scarpellini E.","year":"2008","unstructured":"Scarpellini E.; Tack J.; Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008,17(11),1663-1670","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/ajg.2009.223","volume":"104","author":"Ford A.C.","year":"2009","unstructured":"Ford A.C.; Brandt L.J.; Young C.; Chey W.D.; Foxx-Orenstein A.E.; Moayyedi P.; Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009,104(7),1831-1843","journal-title":"Am J Gastroenterol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2036.2004.02182.x","volume":"20","author":"Schoenfeld P.","year":"2004","unstructured":"Schoenfeld P.; Review article: the safety profile of tegaserod. Aliment Pharmacol Ther 2004,20(Suppl. 7),25-30","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2165\/00002018-200427090-00001","volume":"27","author":"Hasler W.L.","year":"2004","unstructured":"Hasler W.L.; Schoenfeld P.; Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Saf 2004,27(9),619-631","journal-title":"Drug Saf"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/apt.12571","volume":"39","author":"Shin A.","year":"2014","unstructured":"Shin A.; Camilleri M.; Kolar G.; Erwin P.; West C.P.; Murad M.H.; Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014,39(3),239-253","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/BF03256924","volume":"31","author":"Sun J.","year":"2011","unstructured":"Sun J.; Yuan Y.Z.; Holtmann G.; Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study. Clin Drug Investig 2011,31(12),865-875","journal-title":"Clin Drug Investig"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","volume":"55","author":"Barish C.F.","year":"2010","unstructured":"Barish C.F.; Drossman D.; Johanson J.F.; Ueno R.; Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010,55(4),1090-1097","journal-title":"Dig Dis Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/ajg.2012.255","volume":"107","author":"Rao S.","year":"2012","unstructured":"Rao S.; Lembo A.J.; Shiff S.J.; Lavins B.J.; Currie M.G.; Jia X.D.; Shi K.; MacDougall J.E.; Shao J.Z.; Eng P.; Fox S.M.; Schneier H.A.; Kurtz C.B.; Johnston J.M.; A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012,107(11),1714-1724","journal-title":"Am J Gastroenterol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1756283X12443093","volume":"5","author":"Lacy B.E.","year":"2012","unstructured":"Lacy B.E.; Levenick J.M.; Crowell M.; Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol 2012,5(4),233-247","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1053\/j.gastro.2010.07.052","volume":"139","author":"Rao A.S.","year":"2010","unstructured":"Rao A.S.; Wong B.S.; Camilleri M.; Odunsi-Shiyanbade S.T.; McKinzie S.; Ryks M.; Burton D.; Carlson P.; Lamsam J.; Singh R.; Zinsmeister A.R.; Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010,139(5),1549-1558.e1","journal-title":"Gastroenterology"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/ajg.2011.285","volume":"106","author":"Wong B.S.","year":"2011","unstructured":"Wong B.S.; Camilleri M.; McKinzie S.; Burton D.; Graffner H.; Zinsmeister A.R.; Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011,106(12),2154-2164","journal-title":"Am J Gastroenterol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MCG.0b013e3181c64c90","volume":"44","author":"Low K.","year":"2010","unstructured":"Low K.; Hwang L.; Hua J.; Zhu A.; Morales W.; Pimentel M.; A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010,44(8),547-550","journal-title":"J Clin Gastroenterol"},{"key":"ref=87","author":"Gaitonde A.","year":"2009","unstructured":"Gaitonde A.; Mnaojkumar B.; Sonawane S.; Synthesis of tegaserod or a salt thereof. U.S. Patent 2009\/306170 A1, December 102009"},{"key":"ref=88","first-page":"449","volume":"37","author":"Zimmemann A.E.","year":"2002","unstructured":"Zimmemann A.E.; Tegaserod: a 5-HT4 agonist for women with constipation-predominant irritable bowel syndrome. Fomulary 2002,37,449-461","journal-title":"Fomulary"},{"key":"ref=89","first-page":"280","volume":"7","author":"Pfannkuche H.J.","year":"1995","unstructured":"Pfannkuche H.J.; Buhl T.; Gamse R.; Hoyer D.; Mattes H.; Buchheit K.H.; The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol Motil 1995,7,280","journal-title":"Neurogastroenterol Motil"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-3-0348-7259-1_37","author":"Sanger G.J.","year":"1991","unstructured":"Sanger G.J.; Wardle K.A.; Shapcott S.; Yee F.K.;  1991,381-388"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1210\/jcem-54-4-869","volume":"54","author":"Sowers J.R.","year":"1982","unstructured":"Sowers J.R.; Sharp B.; McCallum R.W.; Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 1982,54(4),869-871","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jps.2600551211","volume":"55","author":"Burks T.F.","year":"1966","unstructured":"Burks T.F.; Long J.P.; Catecholamine\u2010induced release of 5\u2013hydroxytryptamine (5\u2010HT) from perfused vasculature of isolated dog intestine. J Pharm Sci 1966,55(12),1383-1386","journal-title":"J Pharm Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0016-5085(98)70203-3","volume":"115","author":"Grider J.R.","year":"1998","unstructured":"Grider J.R.; Foxx-Orenstein A.E.; Jin J.G.; 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998,115(2),370-380","journal-title":"Gastroenterology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.103.053256","volume":"288","author":"Jin J.G.","year":"1999","unstructured":"Jin J.G.; Foxx-Orenstein A.E.; Grider J.R.; Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999,288(1),93-97","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=95","first-page":"1270","volume":"280","author":"Nguyen A.","year":"1997","unstructured":"Nguyen A.; Camilleri M.; Kost L.J.; Metzger A.; Sarr M.G.; Hanson R.B.; Fett S.L.; Zinsmeister A.R.; SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997,280(3),1270-1276","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1365-2982.2002.00328.x","volume":"14","author":"Schikowski A.","year":"2002","unstructured":"Schikowski A.; Thewissen M.; Mathis C.; Ross H.G.; Enck P.; Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002,14(3),221-227","journal-title":"Neurogastroenterol Motil"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"A835","DOI":"10.1016\/S0016-5085(00)85481-5","volume":"118","author":"Coelho A.M.","year":"2000","unstructured":"Coelho A.M.; Rovira P.; Fioramonti J.; Bueno L.; Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology 2000,118(4),A835","journal-title":"Gastroenterology"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1749-6632.1998.tb10217.x","volume":"861","author":"Hoyer D.","year":"1998","unstructured":"Hoyer D.; Fehlmann D.; Langenegger D.; Kummer J.; Giger R.; Mattes H.; Probst A.; Pfannkuche H.J.; High affinity of SDZ HTF-919 related molecules for calf and human caudate 5-HT4 receptors. Ann N Y Acad Sci 1998,861,267-268","journal-title":"Ann N Y Acad Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0165-6147(94)90058-2","volume":"15","author":"Kaumann A.J.","year":"1994","unstructured":"Kaumann A.J.; Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994,15(12),451-455","journal-title":"Trends Pharmacol Sci"},{"key":"ref=100","first-page":"268","volume":"123","author":"Gershon M.D.","year":"2012","unstructured":"Gershon M.D.; Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc 2012,123,268-280","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/j.gastro.2009.08.041","volume":"137","author":"Ghia J.E.","year":"2009","unstructured":"Ghia J.E.; Li N.; Wang H.; Collins M.; Deng Y.; El-Sharkawy R.T.; C\u00f4t\u00e9 F.; Mallet J.; Khan W.I.; Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009,137(5),1649-1660","journal-title":"Gastroenterology"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"G685","DOI":"10.1152\/ajpgi.90685.2008","volume":"296","author":"Bischoff S.C.","year":"2009","unstructured":"Bischoff S.C.; Mailer R.; Pabst O.; Weier G.; Sedlik W.; Li Z.; Chen J.J.; Murphy D.L.; Gershon M.D.; Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol 2009,296(3),G685-G695","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0304-3959(92)90247-9","volume":"49","author":"Traub R.J.","year":"1992","unstructured":"Traub R.J.; Pechman P.; Iadarola M.J.; Gebhart G.F.; Fos-like proteins in the lumbosacral spinal cord following noxious and non-noxious colorectal distention in the rat. Pain 1992,49(3),393-403","journal-title":"Pain"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"42A","DOI":"10.1155\/1999\/846809","volume":"13","author":"Bueno L.","year":"1999","unstructured":"Bueno L.; Fioramonti J.; Effects of inflammatory mediators on gut sensitivity. Can J Gastroenterol 1999,13(Suppl. A),42A-46A","journal-title":"Can J Gastroenterol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-0115(97)02141-1","volume":"70","author":"Friese N.","year":"1997","unstructured":"Friese N.; Diop L.; Chevalier E.; Angel F.; Rivi\u00e8re P.J.; Dahl S.G.; Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul Pept 1997,70(1),1-7","journal-title":"Regul Pept"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","volume":"130","author":"Tack J.","year":"2006","unstructured":"Tack J.; Talley N.J.; Camilleri M.; Holtmann G.; Hu P.; Malagelada J.R.; Stanghellini V.; Functional gastroduodenal disorders. Gastroenterology 2006,130(5),1466-1479","journal-title":"Gastroenterology"},{"key":"ref=107","first-page":"47","volume":"182","author":"Talley N.J.","year":"1991","unstructured":"Talley N.J.; Drug treatment of functional dyspepsia. Scand J Gastroenterol Suppl 1991,182,47-60","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2014-307843","volume":"64","author":"Ford A.C.","year":"2015","unstructured":"Ford A.C.; Marwaha A.; Sood R.; Moayyedi P.; Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015,64(7),1049-1057","journal-title":"Gut"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1365-2982.2005.00715.x","volume":"17","author":"Degen L.","year":"2005","unstructured":"Degen L.; Petrig C.; Studer D.; Schroller S.; Beglinger C.; Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005,17(6),821-826","journal-title":"Neurogastroenterol Motil"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","volume":"10","author":"Mawe G.M.","year":"2013","unstructured":"Mawe G.M.; Hoffman J.M.; Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013,10(8),473-486","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1753-5174.2008.00012.x","volume":"1","author":"Vakil N.","year":"2008","unstructured":"Vakil N.; Kianifard F.; Bottoli I.; Exploratory study of tegaserod for dyspepsia in women receiving PPIs for heartburn. Arch Drug Inf 2008,1(3),79-88","journal-title":"Arch Drug Inf"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/j.1552-4604.1997.tb04785.x","volume":"37","author":"Appel S.","year":"1997","unstructured":"Appel S.; Kumle A.; Hubert M.; Duvauchelle T.; First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J Clin Pharmacol 1997,37(3),229-237","journal-title":"J Clin Pharmacol"},{"key":"ref=113","year":"2017","unstructured":"Available from: Guanidine hydrochloride tablets prescribing information Merck2017","journal-title":"Guanidine hydrochloride tablets prescribing information"},{"key":"ref=114","year":"2007","unstructured":"Available from: Zelnorm (Tegaserod Maleate) Prescribing information Novartis. 2007","journal-title":"Zelnorm (Tegaserod Maleate) Prescribing information"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/DMSO.S166485","volume":"11","author":"Yan L.J.","year":"2018","unstructured":"Yan L.J.; Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent. Diabetes Metab Syndr Obes 2018,11,183-186","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1365-2125.1999.00936.x","volume":"47","author":"Appeal-Dingemanse S.","year":"1999","unstructured":"Appeal-Dingemanse S.; Lemarechal M.O.; Kumle A.; Hubert M.; Legangneux E.; Integrated modeling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral intravenous administration. J Clin Pharmacol 1999,47,483-491","journal-title":"J Clin Pharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2165\/00003088-200241130-00002","volume":"41","author":"Appel-Dingemanse S.","year":"2002","unstructured":"Appel-Dingemanse S.; Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002,41(13),1021-1042","journal-title":"Clin Pharmacokinet"},{"key":"ref=118","first-page":"21","author":"Tegaserod N.DA.","unstructured":"Tegaserod N.DA.; Available from:  (Accessed May 17, 2019),21-200"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/00912709922008524","volume":"39","author":"Zhou H.","year":"1999","unstructured":"Zhou H.; Khalilieh S.; Lau H.; Guerret M.; Osborne S.; Alladina L.; Laurent A.L.; McLeod J.F.; Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol 1999,39(9),911-919","journal-title":"J Clin Pharmacol"},{"key":"ref=120","year":"2002","unstructured":"Jul 22; Available from: ZelnormTM (tegaserod maleate) tablets; prescribing information East Hanover (NJ) Novartis Pharmaceuticas Corporation (Accessed May 17, 2019) 2002","journal-title":"ZelnormTM (tegaserod maleate) tablets;"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s002280000239","volume":"56","author":"Appel-Dingemanse S.","year":"2001","unstructured":"Appel-Dingemanse S.; Hirschberg Y.; Osborne S.; Pommier F.; McLeod J.; Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol 2001,56(12),889-891","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"A1160","DOI":"10.1016\/S0016-5085(00)80460-6","volume":"118","author":"Appeal-Dingemanse S.","year":"2000","unstructured":"Appeal-Dingemanse S.; Rawls J.; Heggland J.; Campestrini J.; S\u00e9chaud R.; Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2000,118(4),A1160","journal-title":"Gastroenterology"},{"key":"ref=123","first-page":"1269","volume":"29","author":"Vickers A.E.M.","year":"2001","unstructured":"Vickers A.E.M.; Zollinger M.; Dannecker R.; Tynes R.; Heitz F.; Fischer V.; In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos 2001,29(10),1269-1276","journal-title":"Drug Metab Dispos"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2165\/00003495-200363110-00013","volume":"63","author":"Wagstaff A.J.","year":"2003","unstructured":"Wagstaff A.J.; Frampton J.E.; Croom K.F.; Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003,63(11),1101-1120","journal-title":"Drugs"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","volume":"118","author":"Prather C.M.","year":"2000","unstructured":"Prather C.M.; Camilleri M.; Zinsmeister A.R.; McKinzie S.; Thomforde G.; Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000,118(3),463-468","journal-title":"Gastroenterology"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","volume":"15","author":"Degen L.","year":"2001","unstructured":"Degen L.; Matzinger D.; Merz M.; Appel-Dingemanse S.; Osborne S.; L\u00fcchinger S.; Bertold R.; Maecke H.; Beglinger C.; Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001,15(11),1745-1751","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1365-2982.2005.00715.x","volume":"17","author":"Degen L.","year":"2005","unstructured":"Degen L.; Petrig C.; Studer D.; Schroller S.; Beglinger C.; Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005,17(6),821-826","journal-title":"Neurogastroenterol Motil"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1517\/14656566.5.11.2369","volume":"5","author":"Patel S.","year":"2004","unstructured":"Patel S.; Berrada D.; Lembo A.; Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2004,5(11),2369-2379","journal-title":"Expert Opin Pharmacother"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0895-4356(03)00027-1","volume":"56","author":"M\u00fcller-Lissner S.","year":"2003","unstructured":"M\u00fcller-Lissner S.; Koch G.; Talley N.J.; Drossman D.; Rueegg P.; Dunger-Baldauf C.; Lefkowitz M.; Subject\u2019s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003,56(4),310-316","journal-title":"J Clin Epidemiol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/tcrm.2007.3.1.107","volume":"3","author":"Layer P.","year":"2007","unstructured":"Layer P.; Keller J.; Loeffler H.; Kreiss A.; Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag 2007,3(1),107-118","journal-title":"Ther Clin Risk Manag"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/gut.52.5.671","volume":"52","author":"Kellow J.","year":"2003","unstructured":"Kellow J.; Chang O.Y.; Thongsawat S.; Mazlam, M. Z.; Yuen, H.; Gwee, K. A.; Bak, Y. T.; Jones, J.; Wagner, A. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003,52,671-676","journal-title":"Gut"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2036.2004.02181.x","volume":"20","author":"Chey W.D.","year":"2004","unstructured":"Chey W.D.; Review article: tegaserod - the global experience. Aliment Pharmacol Ther 2004,20(Suppl. 7),15-19","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2036.2004.02032.x","volume":"20","author":"Bardhan K.D.","year":"2004","unstructured":"Bardhan K.D.; Forbes A.; Marsden C.L.; Mason T.; Short G.; The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain\/discomfort, bloating and constipation: a clinical study. Aliment Pharmacol Ther 2004,20(2),213-222","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00365520310006748","volume":"39","author":"Nyhlin H.","year":"2004","unstructured":"Nyhlin H.; Bang C.; Elsborg L.; Silvennoinen J.; Holme I.; R\u00fcegg P.; Jones J.; Wagner A.; A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004,39(2),119-126","journal-title":"Scand J Gastroenterol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000087049","volume":"71","author":"Layer P.","year":"2005","unstructured":"Layer P.; Keller J.; Mueller-Lissner S.; R\u00fcegg P.; Loeffler H.; Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care. Digestion 2005,71(4),238-244","journal-title":"Digestion"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"II43","DOI":"10.1136\/gut.45.2008.ii43","volume":"45","author":"Thompson W.G.","year":"1999","unstructured":"Thompson W.G.; Longstreth G.F.; Drossman D.A.; Heaton K.W.; Irvine E.J.; M\u00fcller-Lissner S.A.; Functional bowel disorders and functional abdominal pain. Gut 1999,45(Suppl. 2),II43-II47","journal-title":"Gut"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/gut.52.5.621","volume":"52","author":"Grant Thompson W.","year":"2003","unstructured":"Grant Thompson W.; Tegaserod and IBS: a perfect match? Gut 2003,52(5),621-622","journal-title":"Gut"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00210-008-0281-z","volume":"378","author":"Beattie D.T.","year":"2008","unstructured":"Beattie D.T.; Armstrong S.R.; Shaw J.P.; Marquess D.; Sandlund C.; Smith J.A.; Taylor J.A.; Humphrey P.P.; The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008,378(1),139-147","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1471-230X-12-171","volume":"12","author":"Seeger J.D.","year":"2012","unstructured":"Seeger J.D.; Quinn S.; Earnest D.L.; Lembo A.; Kuo B.; Rivero E.; Walker A.M.; The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol 2012,12,171","journal-title":"BMC Gastroenterol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00005344-199907000-00014","volume":"34","author":"Drici M.D.","year":"1999","unstructured":"Drici M.D.; Ebert S.N.; Wang W.X.; Rodriguez I.; Liu X.K.; Whitfield B.H.; Woosley R.L.; Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999,34(1),82-88","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","volume":"35","author":"Tack J.","year":"2012","unstructured":"Tack J.; Camilleri M.; Chang L.; Chey W.D.; Galligan J.J.; Lacy B.E.; M\u00fcller-Lissner S.; Quigley E.M.; Schuurkes J.; De Maeyer J.H.; Stanghellini V.; Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012,35(7),745-767","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2146\/news070044","volume":"64","author":"Thompson C.A.","year":"2007","unstructured":"Thompson C.A.; Novartis suspends tegaserod sales at FDA\u2019s request. Am J Health Syst Pharm 2007,64(10),1020","journal-title":"Am J Health Syst Pharm"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1074248409340158","volume":"14","author":"Anderson J.L.","year":"2009","unstructured":"Anderson J.L.; May H.T.; Bair T.L.; Muhlestein J.B.; Horne B.D.; Carlquist J.F.; Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. J Cardiovasc Pharmacol Ther 2009,14(3),170-175","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1053\/j.gastro.2007.04.057","volume":"132","author":"Pasricha P.J.","year":"2007","unstructured":"Pasricha P.J.; Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007,132(7),2287-2290","journal-title":"Gastroenterology"},{"key":"ref=145","unstructured":"Available from: Novartis.Press release: Novartis suspends US marketing and sales of Zelnorm in response to request from FDA"},{"key":"ref=146","year":"2018","unstructured":"Available from:  Sloan Pharma Briefing Materials, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees (Accessed May 17, 2019)2018","journal-title":"Sloan Pharma Briefing Materials, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees"},{"key":"ref=147","year":"2018","unstructured":"Available from: FDA Briefing Document, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees (Accessed May 17, 2019)2018","journal-title":"FDA Briefing Document, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1592\/phco.24.5.526.33351","volume":"24","author":"Busti A.J.","year":"2004","unstructured":"Busti A.J.; Murillo J.R.J.; Cryer B.; Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004,24(4),526-531","journal-title":"Pharmacotherapy"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1468-2982.2001.00208.x","volume":"21","author":"Gomez-Mancilla B.","year":"2001","unstructured":"Gomez-Mancilla B.; Cutler N.R.; Leibowitz M.T.; Spierings E.L.; Klapper J.A.; Diamond S.; Goldstein J.; Smith T.; Couch J.R.; Fleishaker J.; Azie N.; Blunt D.E.; Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 2001,21(7),727-732","journal-title":"Cephalalgia"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/FPC.0b013e3283469f1d","volume":"21","author":"Haenisch B.","year":"2011","unstructured":"Haenisch B.; B\u00f6nisch H.; Pharmacological characterization of tegaserod at the wild type and 124Cys variant of the human 5-HT1B receptor. Pharmacogenet Genomics 2011,21(7),432-435","journal-title":"Pharmacogenet Genomics"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2009.07.010","volume":"619","author":"Chan K.Y.","year":"2009","unstructured":"Chan K.Y.; de Vries R.; Leijten F.P.; Pfannkuche H.J.; van den Bogaerdt A.J.; Danser A.H.; MaassenVanDenBrink, A. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol 2009,619(1-3),61-67","journal-title":"Eur J Pharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/MJT.0b013e3181b63f21","volume":"17","author":"Serebruany V.L.","year":"2010","unstructured":"Serebruany V.L.; El Mouelhi M.; Pfannkuche H.J.; Rose K.; Marro M.; Angiolillo D.J.; Investigations on 5-HT receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am J Ther 2010,17(6),543-552","journal-title":"Am J Ther"},{"key":"ref=153","unstructured":"US Food"},{"key":"ref=154","unstructured":"US Food"},{"key":"ref=155","unstructured":"EMA - Refusal Assessment Report for Zelnorm Procedure No. EMEA\/H\/C\/621. Available from: (Accessed May 17, 2019)"},{"key":"ref=156","unstructured":"(Accessed May 17, 2019)"}],"container-title":["Anti-Inflammatory &amp; Anti-Allergy Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/174791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/174791\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/174791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T21:00:47Z","timestamp":1614459647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/174791\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":156,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10,15]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871523018666190911121306","relation":{},"ISSN":["1871-5230"],"issn-type":[{"value":"1871-5230","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}